James D. Mccamant
Jim McCamant is editor of the Medical Technology Stock Letter, the oldest biotech newsletter in the country. A nationally recognized authority in biotech investing, he is a constant news source for major media publications, including BusinessWeek, the Wall Street Journal, and Worth Magazine. He lives in Berkeley, California.
Read More
By clicking ‘Sign Up,’ I acknowledge that I have read and agree to Hachette Book Group’s Privacy Policy and Terms of Use
By the Author
Biotech Investing
Biotechnology is indisputably one of the fastest-growing and most promising industries. Virtually immune to swings in the economic cycles, biotech stocks continue to perform steadily…